Get the Stockscreener App
27.54
0.22%
-0.06
After Hours:
28.09
0.55
+2.00%
Oculis Holding Ag stock is traded at $27.54, with a volume of 147.41K.
It is down -0.22% in the last 24 hours and up +8.30% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
See More
Previous Close:
$27.60
Open:
$27.51
24h Volume:
147.41K
Relative Volume:
0.47
Market Cap:
$1.60B
Revenue:
-
Net Income/Loss:
$-118.12M
P/E Ratio:
-12.08
EPS:
-2.2802
Net Cash Flow:
$-82.63M
1W Performance:
+0.73%
1M Performance:
+8.30%
6M Performance:
+28.93%
1Y Performance:
+53.60%
1-Day Range:
$27.38
$28.13
1-Week Range:
$26.90
$28.30
52-Week Range:
$16.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
27.54 | 1.60B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Liquidity Mapping Around (OCS) Price Events - Stock Traders Daily
Tech Rally: Will Oculis Holding AG Equity Warrant benefit from green energy policiesMarket Sentiment Summary & Risk Managed Investment Signals - baoquankhu1.vn
Surprises Report: Is Oculis Holding AG Equity Warrant exposed to political riskPortfolio Risk Summary & Proven Capital Preservation Methods - baoquankhu1.vn
OCS Options Volatility — NASDAQ:OCS - TradingView — Track All Markets
OCS Options Chain — NASDAQ:OCS - TradingView — Track All Markets
Value Recap: Will Oculis Holding AG Equity Warrant benefit from green energy policiesWeekly Profit Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Fund Flows: Whats next for Oculis Holding AG stockShare Buyback & Real-Time Chart Pattern Alerts - baoquankhu1.vn
OCS Stock Price, Quote & Chart | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Director Riad Sherif's Oculis RSUs vested and settled on April 5 - Stock Titan
Oculis Holding AG (OCSAW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces 2026 Investor Conference Participation and Key Updates - Intellectia AI
Oculis to Participate in Upcoming Investor Conferences - Bitget
Oculis Holding AG Announces Upcoming Investor Conferences and Pipeline Updates for 2026 Progress - Quiver Quantitative
Investment Report: Can Oculis Holding AG Equity Warrant stock double in the next yearPortfolio Risk Summary & Capital Efficient Trade Techniques - baoquankhu1.vn
Assessing Oculis Holding (OCS) Valuation After EMA PRIME Designation For Privosegtor - Sahm
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate - Sahm
Risk Check: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS - MarketBeat
Oculis Holding AG renews $100 million at-the-market offering program - Investing.com
Why (OCS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Stifel raises Oculis stock price target to $50 on pipeline progress - Investing.com
OCS SEC FilingsOculis Holding 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Oculis Holding AG Equity Warrant attractive for institutional investorsMarket Risk Analysis & Real-Time Price Movement Reports - baoquankhu1.vn
Can Oculis Holding AG continue delivering strong returnsCEO Change & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Aug Analyst Calls: Should I invest in Oculis Holding AG before earningsQuarterly Profit Review & Reliable Volume Spike Alerts - baoquankhu1.vn
Earnings Recap: How does Oculis Holding AG compare to its peersMarket Sentiment Summary & Target Return Focused Picks - baoquankhu1.vn
Oculis (NASDAQ:OCS) Trading Up 9.2%Time to Buy? - MarketBeat
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - The Manila Times
Oculis Announces European Medicines Agency PRIME - GlobeNewswire
Oculis Holding AG's Privosegtor Receives PRIME Designation from EMA for Treatment of Optic Neuritis, Following FDA Breakthrough Therapy Status - Quiver Quantitative
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a ... - Caledonian Record
Oculis drug for sight-threatening optic neuritis wins EMA PRIME - Stock Titan
OCS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bearish Setup: Whats next for Oculis Holding AG stock2026 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Analyst Upgrade: Should you avoid Oculis Holding AG Equity Warrant stock right now2026 Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis - Bitget
EPS Watch: Can Oculis Holding AG Equity Warrant be the next market leader2026 Chart Watch & Safe Entry Momentum Stock Tips - baoquankhu1.vn
OCS PE Ratio & Valuation, Is OCS Overvalued - Intellectia AI
Is Positive Privosegtor Phase 2 Optic Neuritis Data Altering The Investment Case For Oculis Holding (OCS)? - Sahm
Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5% - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS - MarketBeat
Beyeotech's 2.44M-share stake in Oculis (OCS) equals 4.14% of float - Stock Titan
Oculis discloses annual equity award for executive committee member - Stock Titan
Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference Summary - Quartr
Understanding Momentum Shifts in (OCS) - Stock Traders Daily
Loss Report: Is Oculis Holding AG Equity Warrant a top pick in the sectorTrade Risk Summary & Technical Pattern Recognition Alerts - baoquankhu1.vn
Growth Recap: Is Oculis Holding AG Equity Warrant stock a value trap2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Decliners: Will Oculis Holding AG benefit from green energy policiesWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Sentiment Review: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):